Author Archives: Alberto Molano, PhD

ConSynance Therapeutics Will Participate in Prader-Willi Trial Consortium

ConSynance Therapeutics, a biotechnology company that has developed two new candidate medicines for Prader-Willi syndrome (PWS), announced that it has joined the PWS Clinical Trial Consortium. The PWS Clinical Trial Consortium was established in 2015 to accelerate clinical trials in PWS by promoting multidisciplinary, pre-competitive, and international collaboration among stakeholders…

Disgusting Food Scenes Evoke Abnormal Brain Responses in Patients with Prader-Willi Syndrome, Study Reports

Disgusting food scenes failed to activate primitive limbic structures in the brains of people with Prader-Willi syndrome (PWS), but cortical responses ­­­­— where conscious sensations are processed ­­­­— were almost normal, a study reports. The study, “Lack of Response to Disgusting Food in the Hypothalamus and Related Structures in Prader…

Parents of PWS Children Give Telehealth Training Positive Reviews

A six-week remote parent-training intervention for children with Prader-Willi syndrome (PWS) got good acceptability and satisfaction scores from parents, supporting the use of telehealth to manage the social and emotional impairments of children with this rare condition, a study reports. The study, “The PRETEND Program: Evaluating the Feasibility of…